» Articles » PMID: 20214678

Epidemiology of Amyotrophic Lateral Sclerosis in Isfahan, Iran

Overview
Journal Eur J Neurol
Publisher Wiley
Specialty Neurology
Date 2010 Mar 11
PMID 20214678
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Few studies are carried out on the epidemiology of amyotrophic lateral sclerosis (ALS) in Middle East with no reports from Iran.

Objective: To determine the epidemiological and clinical features of ALS amongst the Iranian population living in Isfahan, Iran.

Methods: Medical records of all hospitals with a neurology department and outpatient neurology clinics in Isfahan province from 2002 to 2006 were reviewed, and all patients with the diagnosis of ALS according to El Escorial diagnostic criteria were extracted and related demographic and clinical data were gathered and analyzed.

Results: We found 98 new patients (66 men and 32 women) with definite, probable, or possible ALS. The average annual incidence was 0.42/100,000, with the highest incidence rate amongst those aged 70-74. On 21 March 2006, the crude prevalence was 1.57/100,000. Median survival from onset was 48 months (95% confidence interval 34-61) and survival rates for 1, 3,and 5 years after the onset were 94%, 66%, and 32%, respectively.

Conclusions: The incidence and prevalence of ALS in the Iranian population seems to be lower compared to other populations and the survival of patients was longer than previously reported.

Citing Articles

Iranian clinical practice guideline for amyotrophic lateral sclerosis.

Boostani R, Olfati N, Shamshiri H, Salimi Z, Fatehi F, Hedjazi S Front Neurol. 2023; 14:1154579.

PMID: 37333000 PMC: 10272856. DOI: 10.3389/fneur.2023.1154579.


Global Prevalence and Incidence of Amyotrophic Lateral Sclerosis: A Systematic Review.

Wolfson C, Gauvin D, Ishola F, Oskoui M Neurology. 2023; 101(6):e613-e623.

PMID: 37308302 PMC: 10424837. DOI: 10.1212/WNL.0000000000207474.


Time-trend evolution and determinants of sex ratio in Amyotrophic Lateral Sclerosis: a dose-response meta-analysis.

Fontana A, Marin B, Luna J, Beghi E, Logroscino G, Boumediene F J Neurol. 2021; 268(8):2973-2984.

PMID: 33630135 DOI: 10.1007/s00415-021-10464-2.


Diagnostics of Amyotrophic Lateral Sclerosis: Up to Date.

Stetkarova I, Ehler E Diagnostics (Basel). 2021; 11(2).

PMID: 33546386 PMC: 7913557. DOI: 10.3390/diagnostics11020231.


Age-specific ALS incidence: a dose-response meta-analysis.

Marin B, Fontana A, Arcuti S, Copetti M, Boumediene F, Couratier P Eur J Epidemiol. 2018; 33(7):621-634.

PMID: 29687175 DOI: 10.1007/s10654-018-0392-x.